Opinion|Videos|October 7, 2024
SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3
Key Takeaways
- The SHASTA-2 study evaluates a novel therapeutic agent in patients with advanced solid tumors, focusing on progression-free survival and overall response rate.
- It employs a randomized, double-blind, placebo-controlled design to ensure robust data collection and analysis.
Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis.
Advertisement
Video content above is prompted by the following:
Please provide a brief overview of the SHASTA-2 study.
Advertisement
Related to this article
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
4
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
5